Loading...

Osteoporosis Drugs Market Expected to Reach $10 Billion by 2026

 
 

quote The demand for osteoporosis drugs is on a rise, owing to surge in incidence of osteoporosis globally. Furthermore, rise in healthcare expenditure leads to easy availability of osteoporosis drugs, which fuels the market growth. quote

Onkar Sumant
Manager, Healthcare at Allied Market Research

Get 20% Free Customization In This Report
Follow us on Social Media:       
 

According to a new report published by Allied Market Research, titled, "Osteoporosis Drugs Market by Drug Class, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019–2026," the global osteoporosis drugs market size was valued at $8 billion in 2018, and is expected to reach $10 billion by 2026, registering a CAGR of 3.9% from 2019 to 2026.

Osteoporosis is a medical condition which involves the weakening of the bones. This medical condition is caused due to the overexpression of the parathyroid hormone. Moreover, the weak bones are porous and susceptible to serious fractures. Therefore, osteoporosis has a significant impact on quality of life of patients such as the condition leads to limited mobility. Thus, this medical condition requires treatment which includes the administration of drugs such as bisphosphonates selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors and others. Furthermore, these drugs are administered through different routes in the body. For instance, some osteoporosis drugs are administered through the oral route whereas others are administered through the intravenous route. 

The major factor that contributes toward the growth of global osteoporosis drugs market include rise in prevalence of osteoporosis. Furthermore, other factors that boost osteoporosis drugs market growth include surge in geriatric population across the globe and rise in adoption of sedentary lifestyle worldwide. However, side effects of osteoporosis drugs, and the time-consuming drug approval process restrain the growth of the global osteoporosis drugs market. Conversely, high growth potential in developing economies is expected to offer lucrative opportunities during the forecast period.

The osteoporosis drugs market size is studied on the basis of drug class, route of administration, and region to provide a detailed assessment of the market. By drug class, it is segmented into bisphosphonates, selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others. Depending on route of administration, it is fragmented into oral, injectable and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

By drug class, the bisphosphonates segment acquired the major share of osteoporosis drugs market in 2018 owing to increase in investment in R&D of advanced novel bisphosphonates drugs by major players.  However, rank ligand inhibitors segment is expected to exhibit fastest growth rate during the forecast period owing to the fact that these drugs are used treat bone metastasis by acting as a chemoattractant to bone for tumor cells that express its receptor, RANK. Thus, the inhibition of the RANKL-RANK pathway acts as an ideal treatment for bone metastasis which makes them a preferred choice of drug.

By route of administration, the oral segment acquired for the major share of the osteoporosis drugs market owing to large number of osteoporosis medications which are available as oral drugs in the market. However, the injectable segment is expected to grow at the fastest CAGR during the forecast period owing to factors such as rise in need for drugs which exhibit enhanced bioavailability, and act rapidly.

By region, North America accounted for the major osteoporosis drugs market share in 2018 and is expected to continue this trend, owing to easy availability of osteoporosis drugs. Moreover, surge in the incidence of osteoporosis is another major reason that contributes to the growth of this market. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period attributed to the increase in awareness regarding the use of osteoporosis drugs for the treatment of osteoporosis. Moreover, the constantly evolving life science industry drives the growth of the market in developing economies such as India, China, and Malaysia.

Key Findings of the Study:

  • Bisphosphonates occupied more than one-third share of the global osteoporosis drugs market in 2018.
  • The RANK ligand inhibitors segment is anticipated to grow with the highest CAGR throughout the forecast period.
  • The oral segment in drug class accounted for more than more than half the share of the market in 2018.
  • Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com

 

For Media Inquiries, Please Contact

Ram D
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at
media@alliedmarketresearch.com

 
 

First time buyer?
Check offers and discount on this report
To get this report

 
Click Here
 
 

quote Osteoporosis Drugs Market by Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others) and Route of Administration (Oral, Injectable, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026 quote

View Report
 
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers

 

Featured Readings

 
 

Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

 
Get Industry Data Alerts
 

Buy Full Version
"Osteoporosis Drugs Market"
Purchase Enquiry